$0.780
-0.022 (-2.88%)At close
QSI News
QSI Events
Kodiak AI Borrow Rate Increases to 210.02%
Latest data shows the largest indicative borrow rate increases among liquid option names include: Kodiak AI, Inc. Common Stock (KDK) 210.02% +48.07, Eagle Nuclear Energy Corp (NUCL) 147.89% +1.58, Draganfly (DPRO) 12.06% +0.92, Rezolve AI Ltd (RZLV) 21.96% +0.92, Humacyte (HUMA) 22.50% +0.83, Innoviz (INVZ) 3.20% +0.50, Angion Biomedica Corp (ELTX) 5.12% +0.50, Prairie Operating Co (PROP) 5.08% +0.34, Energy Transfer (ET) 2.22% +0.34, and Quantum Si (QSI) 1.50% +0.33.
Proteus Reports Q1 Revenue of $258K, Below Consensus
Reports Q1 revenue $258K, consensus $299K. "We delivered a strong quarter of Proteus execution, achieving the key development milestones we outlined at our Investor & Analyst Day in November 2025. Most notably, we achieved automated sequencing runs on integrated Proteus instruments bringing together all the core elements of the system planned for the launch configuration spanning instrumentation, KinetIQ(TM) Array, Sequencing chemistry and data analysis, all without user intervention once the run is initiated," said Jeff Hawkins, President and Chief Executive Officer. "While there is more work ahead, the momentum we are building across all parts of the Proteus development program is encouraging and reinforces our confidence in the roadmap we are executing."
Quantum-Si Achieves Sequencing on Integrated Proteus Instruments
Quantum-Si Incorporated demonstrated sequencing on integrated Proteus instruments. The company said, "This milestone was achieved using a developmental sequencing kit, the KinetIQ Array, and fully integrated Proteus instruments. The developmental sequencing kit used to achieve this milestone can detect 17 amino acids, a rapid improvement in only four months since adding the detection of the 15th amino acid to the commercially available sequencing kit in December of 2025. To demonstrate the full workflow, a sample, sequencing reagents and kinetic array were placed in the instrument drawer by the user and the run was initiated. The entire process from setting up the sequencing reaction to loading the sample into the KinetIQ Array through to data acquisition was fully automated by the Proteus instrument without any user intervention."
Quantum-Si Releases New Study on Human Cohesin Function in Yeast
Quantum-Si Incorporated announced a new manuscript available via pre-print on bioRxiv from researchers out of the University of British Columbia and the B.C. Cancer Research Institute. In the pre-print titled "Heterologous expression of the human cohesin complex in Saccharomyces cerevisiae results in a dominant-negative phenotype", the researchers expressed key human chromosome-organizing proteins in yeast cells. They hypothesized that the human cohesins were forming complexes and disrupting the activity of endogenous yeast cohesins. This matters for cancer drug development because problems with cohesin can drive genome instability in tumors, pointing to new ways to target cancer cells. "We are excited to see the first manuscript published by international researchers," said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. "In this study, single-molecule protein sequencing enabled the researchers at University of British Columbia and B.C. Cancer Research Institute to directly identify hybrid cohesin complexes, demonstrating the value of our technology as a foundational tool for mechanistic biology research and therapeutic discovery."
Quantum-Si Completes Sequencing on Proteus Prototype System
Quantum-Si has completed the sequencing of multiple samples provided by an existing Platinum Pro customer on a Proteus prototype system. The testing included sequencing the samples on both Platinum Pro and a Proteus prototype system. For Platinum Pro, the Company used the commercially available Version 3 Library Preparation Kit and Version 4 Sequencing Kit. For the Proteus prototype, the Company used the Version 3 Library Preparation Kit and a developmental sequencing kit that contains the latest amino acid recognizer set. The sequencing results were consistent with the information that the Company shared at the November 2025 Investor and Analyst Day demonstrating that Proteus was far exceeding Platinum Pro performance across all relevant metrics. Specifically, the Proteus prototype and developmental sequencing kit demonstrated significantly improved amino acid coverage, longer read lengths, more peptides identified and greater sequencing output even when normalized for the difference in the number of nanowells on a Platinum Pro chip versus the Proteus KinetIQ array. "We are very excited to have successfully completed the sequencing of our first customer samples on the Proteus prototype system," said Jeff Hawkins, CEO. "Being able to demonstrate that the Proteus prototype system exceeds Platinum performance across all metrics on real world samples is an important milestone in the development of this new platform. We expect sequencing performance to continue to increase from here as we work to further optimize the Proteus system into our final commercial offering. This is just one of many customers who have indicated interest in providing samples for sequencing on the Proteus prototype. We are working closely with our manufacturing partners to increase the rate of delivery of integrated Proteus systems to meet both internal R&D demand and provide additional capacity to be able to offer customer sample testing to the market through a formal pre-launch sample evaluation program. We look forward to providing more updates on this program on our next earnings call."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.